Novartis acquires IFM Tre. Its drugs target the innate immune system - STAT

Novartis acquires IFM Tre. Its drugs target the innate immune system - STAT

STAT Plus: Novartis acquires Boston-based IFM Tre for work on drugs to modify the immune system

By KATE SHERIDAN

RUBY WALLAU FOR STAT

IFM Tre, a young Boston-based startup, is being acquired by Novartis for more than $300 million. It focuses on drugs to modify the innate immune system.

READ MORE